Quick Facts

• 23% of U.S. households now use GLP-1 medications, projected to reach 35% of food and beverage purchases by 2030
• Grocery spending drops 5.3% within six months of starting GLP-1s, creating a $9 billion annual reduction in food sales
• Apparel retailers face $13 billion opportunity but also operational challenges as customers change sizes during weight loss

The rapid adoption of GLP-1 weight loss medications is reshaping retail across multiple categories. Nearly 23% of U.S. households use these drugs, with J.P. Morgan projecting 25 million Americans on GLP-1 treatment by 2030.

Grocery retailers face the steepest impact. Households reduce food spending by 5.3% within six months of starting treatment. Higher-income households cut spending by more than 8%. The national grocery spending reduction totals approximately $9 billion annually.

Savory snacks see the largest declines, dropping 10%. Sweets, baked goods and cookies show similar decreases. Fast-food spending falls 8% as appetite suppression changes eating patterns.

Apparel retailers encounter both opportunity and operational challenges. Bernstein estimates a $13 billion annual boost in clothing spending as customers buy new wardrobes during weight loss. However, retailers struggle with size volatility.

“The same customer is moving across multiple sizes, but the time frame of developing our product assortment and sizing our product is not built for that volatility,” industry experts note.

Plus-size retailer Destination XL reported fourth quarter sales down 6% year-over-year with a $29.6 million net loss. CEO Harvey Kanter said 25% of customers use GLP-1s, creating business volatility. “They are losing weight and trying not to buy clothes until they are done with that journey,” Kanter said.

Fashion retailers with $1 billion in annual sales could lose up to $20 million in margin and another $20 million in unrealized sales from size curve inaccuracy.

The trend creates new opportunities beyond traditional retail. Perfume sales increased 23% as people seek sensory inputs no longer satisfied by food. Weekly exercise among GLP-1 users doubled from 35% to 71%, driving athletic wear demand.

GLP-1 users follow predictable weekly cycles tied to injection schedules. Days 1-3 bring appetite suppression and nausea sensitivity. Days 4-5 stabilize. Days 6-7 see appetite return and food re-engagement.

One in four GLP-1 users switched grocery stores since beginning treatment, the highest level since mid-November 2025. This shopping pattern shift forces retailers to reconsider customer retention strategies.

The economic impact extends beyond individual categories. Users reduce calorie intake by more than 20%, often eliminating high-cost snacks, fast food and alcohol. This creates household budget surplus that flows to other retail categories.

Retailers must adapt operational systems for this new reality. Apparel companies need continuous size evaluation and monitoring. Food manufacturers face long-term demand shifts requiring changes to package sizes, product formulations and marketing strategies.

Read more: Are retailers ready for what the weight-loss boom requires?